Campone Mario, Berton-Rigaud Dominique, Bourbouloux Emmanuelle, Sophie Sadot, Zanetti Alain, Frenel Jean-Sébastien
Institut du cancer Nantes-Atlantiques, centre René-Gauducheau, Saint-Herblain, France.
Bull Cancer. 2011 Feb;98(2):154-63.
The molecular classification of Perou and Sørlie breast tumors has to streamline, systematize and make effective use of targeted therapies against specific molecular subtypes, including breast HER2 positive. Trastuzumab and lapatinib are currently the two therapies targeting HER2, which have demonstrated their effectiveness in clinical practice. This literature review aims to make the data points on pertinent and useful data for physicians in daily.
佩鲁和索尔利提出的乳腺癌分子分类必须进行简化、系统化，并有效利用针对特定分子亚型的靶向治疗方法，包括HER2阳性乳腺癌。曲妥珠单抗和拉帕替尼是目前两种针对HER2的治疗药物，它们在临床实践中已证明了自身的有效性。这篇文献综述旨在为医生日常工作提供相关且有用的数据要点。
